Personalised vaccine to be tested in patients with kidney cancer
Scientists at the Dana-Farber Cancer Institute in Boston, USA, are [...]
Nivolumab-ipilimumab combination delays the need for additional treatment in kidney cancer patients
A recent analysis of data from the phase 3 Checkmate-214 [...]
First immunotherapy combination of ipilimumab plus nivolumab recommended by CHMP
We have just learnt the news that the Committee for Medicinal Products [...]
ESMO 2018: Longer treatment-free survival for ipilimumab/nivolumab combination versus sunitinib
Analysis of the phase 3 CheckMate-214 study has shown that [...]
Managing immune-related adverse events
Immune-related adverse events (irAEs) are side effects that can develop [...]
Joint statement from the EAU and IKCC about the rejection of the ipilimumab plus nivolumab combination for kidney cancer by the EMA
The European Association of Urology (EAU) Renal Cell Cancer Guidelines [...]
IKCC statement on the negative opinion by the CHMP for the ipilimumab/nivolumab combination
The International Kidney Cancer Coalition (IKCC) have released the following [...]
Latest clinical trial results for the treatment of kidney cancer
These short videos explain the latest results from the following [...]
Negative EMA opinion for the ipilimumab/nivolumab combination
Yesterday it was announced that the combination of ipilimumab and [...]
Treatment of metastatic kidney cancer in older patients
A recent meta-analysis evaluating the efficacy of first- and second-line [...]
